Sanofi CEO on why prominent doctors are mistaken when they say cancer drug Zaltrap is too costly.

Greece unveils it's new budget, UK Finance Minister outlines spending cuts, Sanofi-Aventis makes hostile bid for Genzyme and new regulations may be on the cards for Swiss banks.

The head of biotech company Genzyme said his company would make a perfect fit with Sanofi-Aventis, but not at $69 a share. Wall Street ended little changed after a dismal August.

European banks and oil stocks drop with lower quarterly results from Morgan Stanley.

Joya Doss

A Food and Drug Administration panel unanimously rejected a weight-loss drug from Sanofi-Aventis, on concerns the drug increases the number of psychiatric events like depression and suicidal thinking ...

Joya Doss

Drug manufacturer Sanofi-Aventis says people suffering from depression should not take the weight-loss drug rimonabant; the FDA is expected to decide whether rimonabant can be sold in the U.S. by the ...